Korro Bio
Korro Bio
KRRO
NASDAQ
22.69
USD
1.43%
About
Korro Bio, Inc. is a biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit.
By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Its Oligonucleotide Promoted Editing of RNA (OPERA) is a foundational platform for RNA editing, which is designed to edit RNA in vivo by delivering an oligonucleotide guide that can target specific RNA sequences. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD), that has the potential to be disease-modifying and provide a differentiated therapeutic option..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 62.9K |
| Three Month Average Volume | 1.8M |
| High Low | |
| Fifty-Two Week High | 97.91 USD |
| Fifty-Two Week Low | 9.15 USD |
| Fifty-Two Week High Date | 27 Mar 2024 |
| Fifty-Two Week Low Date | 30 Oct 2023 |
| Price and Volume | |
| Current Price | 47.72 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | 7.93% |
| Thirteen Week Relative Price Change | -13.09% |
| Twenty-Six Week Relative Price Change | -11.97% |
| Fifty-Two Week Relative Price Change | 58.68% |
| Year-to-Date Relative Price Change | -15.92% |
| Price Change | |
| One Day Price Change | -4.48% |
| Thirteen Week Price Change | -6.98% |
| Twenty-Six Week Price Change | -3.20% |
| Five Day Price Change | 5.83% |
| Fifty-Two Week Price Change | 98.83% |
| Year-to-Date Price Change | -0.44% |
| Month-to-Date Price Change | 2.49% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 21.19511 USD |
| Book Value Per Share (Most Recent Quarter) | 21.34464 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 21.19511 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 21.34464 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -17.36039 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -53.07715 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -30.5064 USD |
| Normalized (Last Fiscal Year) | -53.07715 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -53.07715 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -30.5064 USD |
| Including Extraordinary Items (Last Fiscal Year) | -53.07715 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -30.5064 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 20.72595 USD |
| Cash Per Share (Most Recent Quarter) | 16.96498 USD |
| Cash Flow Per Share (Last Fiscal Year) | -50.70358 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -16.33668 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -18.52749 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -289 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -365.78% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -374.74% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -365.87% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -18.47% |
| Tangible Book Value (5 Year) | 35.90% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 78.21% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 83.89% |
| EPS Change (Trailing Twelve Months) | 67.92% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 3 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -157,434,000 |
| Net Debt (Last Fiscal Year) | -166,150,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 2 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 9 |
| Current Ratio (Most Recent Quarter) | 13 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -75,119,000 |
| Free Cash Flow (Trailing Twelve Months) | -100,519,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -167 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -47.34% |
| Return on Assets (Trailing Twelve Months) | -56.06% |
| Return on Assets (5 Year) | -31.55% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -67.90% |
| Return on Equity (Trailing Twelve Months) | -75.75% |
| Return on Equity (5 Year) | -47.33% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -53.69% |
| Return on Investment (Trailing Twelve Months) | -59.82% |
| Return on Investment (5 Year) | -36.48% |